Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer

Esposito, Vincenzo; Baldi, Alfonso; Luca, Antonio De; Tonini, Giuseppe; Vincenzi, Bruno; Santini, Daniele; Persichetti, Paolo; Mancini, Alessandro; Citro, Gennaro; Baldi, Feliciano; Groeger, A M; Caputi, M

doi:10.1136/jcp.2004.023531

Cited by 27 publications

(19 citation statements)

References 32 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have indicated that, as the inactivation of RB tumor suppressor gene stimulates the development of SCLCs, the inactivation of p16 expression is the main cause of cell losing growth control in NSCLCs [12,13,15,16]. The results may support this notion, as it was determined that tissues from smokers with NSCLCs often had the loss of p16 expression when compared with their nonsmoking counterparts.…”

Section: Discussionsupporting

confidence: 69%

“…Nakata et al [16,19] proposed that p16 gene might have a correlation with the development of lung cancer, but did not have any relevance with the prognosis. In contrast, both NSCLC non-small cell lung cancer Singhal et al [17,20] and Abdulkader et al [18,21] found a correlation of the loss of p16 expression with worse prognoses of NSCLC patients.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer

Xiao

Gao

et al. 2010

Med Oncol

View full text Add to dashboard Cite

This study was designed to evaluate the expression of C-erbB-2 and p16 in lung cancers using tissue microarray technology and to determine their clinical and pathological significance. Immunohistochemical C-erbB-2 and p16 expressions and their associations with clinical and pathological features were analyzed in two tissue microarrays. The membranous and cytoplasmic expression rates of C-erbB-2 were 40.5 and 66.5% in non-small cell lung cancers (NSCLCs), and 0 and 9.5% in small cell lung cancers (SCLCs), respectively. The nuclear and cytoplasmic expression rates of p16 were 11.5 and 32.2% in NSCLs, and 45 and 80% in SCLCs, respectively. The cytoplasmic expression of both C-erbB-2 and p16 was more frequent than the membranous expression of C-erbB-2 and the nuclear expression of p16. The rates of overexpression of C-erbB-2 and loss of p16 expression were significantly higher in NSCLCs than in SCLCs (P < 0.05). Neither C-erbB-2 nor p16 expression was significantly associated with age, tumor grade or stage, presence of lymph node metastasis or survival duration. The abnormal expressions of p16 and C-erbB-2 may play a role in the progression of lung cancers. The variations in the expression patterns of C-erbB-2 and p16 between NSCLCs and SCLCs may aid the molecular classification of lung cancer. The abnormal expression of p16 may be involved in the development of NSCLCs, and the overexpression of C-erbB-2 in NSCLCs indicates that it can be a candidate target for gene therapy.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 98%

Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer

Xiao

Gao

et al. 2010

Med Oncol

View full text Add to dashboard Cite

show abstract

“…Difficulties in assessing this issue are due to the fact that cyclin D1 expression in NSCLC has mainly been analyzed immunohistochemically [37,60,61] and most available antibodies detect total cyclin D1 or the C-terminus of cyclin D1a [62]. In addition, cyclin D1b is usually present in quantities below the sensitivity of available assays [63].…”

Section: Cyclins In Nsclcmentioning

confidence: 99%

Prognostic and Predictive Value of Cell Cycle Deregulation in Non-Small-Cell Lung Cancer

2012

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is among the most frequently diagnosed malignancy and a leading cause for cancer mortality worldwide. Despite various efforts, practical prognostic and predictive markers are still few. We review recent findings concerning the cell cycle in NSCLC and discuss prognostic and predictive aspects as well as the challenge of targeted therapeutic approaches. Deregulation of the cell cycle is a common event in NSCLC. Usually, several defects of cell cycle regulation are concomitant and have a cumulative adverse effect on prognosis. Therefore, analysis of a variety of interacting molecules is desirable for adequate deductions. Immunohistochemical interpretations should include the subcellular staining localization, since this can reflect the functional properties of a protein. Overexpression of cyclins, especially D-type cyclins, has repeatedly been associated with poor prognosis in NSCLC. Predictive data is less conclusive; however, loss of the expression of cyclin-dependent kinase inhibitors seems to correlate with sensitivity to antiproliferative drugs. Various inhibitors of Aurora kinases are currently being evaluated regarding their potential as targeted therapies in NSCLC. In conclusion, the cell cycle offers several prognostic, predictive and therapeutic possibilities in NSCLC, many still developmental. Progress in this field has the potential to improve the current scenario for NSCLC patients.

show abstract

“…A pathological change links a CT image to molecular biology, thus making it possible to investigate the internal relationship between a CT scan and biological behavior. As a type of oncogene, cyclin D1 is an important cyclin protein in the G1 phase of the cell cycle [1][2][3] . The expression of cyclin D1 in peripheral non-small cell lung cancer has been studied using streptavidin peroxidase (SP) immunohistochemistry.…”

Section: Introductionmentioning

confidence: 99%

HRCT scans of peripheral non-small cell lung cancers and their relationship with cyclin D1 expression: a longitudinal study

et al. 2008

Chin. J. Clin. Oncol.

View full text Add to dashboard Cite

OBJECTIVE To investigate cyclin D1 expression in peripheral lung cancers and its relationship with CT signs and prognosis. METHODS Cyclin D1 expression in peripheral lung cancers and its relationship with the CT imaging and prognosis were analyzed retrospectively by means of SP immunohistochemistry and spiral CT scanning in 92 patients with peripheral lung cancer verię ed by pathology. RESULTS Cyclin D1 expression was related to deep lobulation, spiculate protuberance, short thin spinules sign and mediastina lymph node metastasis. Cyclin D1 expression was not related to tumor size, cavity, pleural indentation, histological type, differentiation, tumor TNM stage, age or sex. Cyclin D1 was a negative prognostic factor whose over-expression indicated a poor prognosis. CONCLUSION Cyclin D1 expression may play an important role in the occurrence, progress and CT scan results of lung cancers. Cyclin D1 was a negative factor whose over-expression implied a poor prognosis. Detection of the cyclin D1 and observation of the CT scan can be considered as indexes of clinical diagnosis and prognostic evaluation. K E Y

show abstract

Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer

Cited by 27 publications

References 32 publications

Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer

Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer

Prognostic and Predictive Value of Cell Cycle Deregulation in Non-Small-Cell Lung Cancer

HRCT scans of peripheral non-small cell lung cancers and their relationship with cyclin D1 expression: a longitudinal study

Contact Info

Product

Resources

About